In previous studies using the doxycycline-inducible transgenic Tafazzin shRNA-mediated model [54, 55], in which wildtype Tafazzin levels are reduced via doxycycline feeding in the in utero and postnatal stages, 50% of the 2-month-old TazKD♂ mice demonstrated neutropenia, as did 20% of the wt controls (with doxycycline administered to both). Here, TAFAZZIN is linked to neutropenia.